Decrease in PSA ≥50% of baseline from trial and prolongation of PSADT resulting from therapy was defined as a clinically significant effect of grape skin phenols as a treatment and would allow delaying androgen deprivation hormonal therapy in men with BRC prostate cancer. The gene discussed is KLK3; the disease is prostate carcinoma.